83 related articles for article (PubMed ID: 20189492)
1. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years.
Tregnaghi MW; Voelker R; Santos-Lima E; Zambrano B
Vaccine; 2010 Apr; 28(20):3595-601. PubMed ID: 20189492
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
Raz R; Koren R; Bass D
Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
Schiff GM; Sherwood JR; Zeldis JB; Krause DS
J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
Heron L; Selnikova O; Moiseieva A; Van Damme P; van der Wielen M; Levie K; Hoet B; Stoffel M
Vaccine; 2007 Apr; 25(15):2817-22. PubMed ID: 17276552
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of HBV vaccine during stated shelf-life.
Gloriani NG; Srinivasa K; Bock HL; Hoet B
Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
10. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
[TBL] [Abstract][Full Text] [Related]
12. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
[TBL] [Abstract][Full Text] [Related]
13. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
Jafarzadeh A; Zarei S; Shokri F
Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
[TBL] [Abstract][Full Text] [Related]
16. [Observation on two kinds of recombinant hepatitis B vaccines used in populations with different immunity].
Zhang H; Ma JX; Gong XH; Liu LR; Wu K; Luo FJ; Zhao W; Zeng ZL; Bai YH; Sun LL; Xu W
Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Aug; 27(8):690-3. PubMed ID: 17172109
[TBL] [Abstract][Full Text] [Related]
17. [The immunogenicity and safety of 10 microg recombination yeast hepatitis B vaccine applied in expanded population].
Fu QP; He H; Li L; Chen HP; Zeng YX; Liu QL; Fang G; Dong CM; Guo SH; Li HG; Wang HY; He CS; Zhou SZ; Li L; Gu SN; Zhang ZF; Dai M
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Oct; 43(10):903-6. PubMed ID: 20137473
[TBL] [Abstract][Full Text] [Related]
18. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders.
Lin C; Zhu J; Zheng Y; Chen Y; Wu Z; Chong Y; Gao Z
J Infect; 2010 Apr; 60(4):264-70. PubMed ID: 20138189
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
